Analysts Are Bullish on Top Healthcare Stocks: Axsome Therapeutics (AXSM), Iovance Biotherapeutics (IOVA)

Business Insider

12-05-2025

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Axsome Therapeutics (AXSM – Research Report), Iovance Biotherapeutics (IOVA – Research Report) and Alector (ALEC – Research Report) with bullish sentiments.
Protect Your Portfolio Against Market Uncertainty
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Axsome Therapeutics (AXSM)
Morgan Stanley analyst Vikram Purohit maintained a Buy rating on Axsome Therapeutics yesterday and set a price target of $190.00. The company's shares closed last Friday at $107.76.
According to TipRanks.com, Purohit is a 1-star analyst with an average return of -4.1% and a 37.7% success rate. Purohit covers the Healthcare sector, focusing on stocks such as Recursion Pharmaceuticals, BioMarin Pharmaceutical, and Arcutis Biotherapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Axsome Therapeutics with a $176.07 average price target, a 61.7% upside from current levels. In a report issued on April 29, RBC Capital also maintained a Buy rating on the stock with a $193.00 price target.
Wells Fargo analyst Yanan Zhu maintained a Buy rating on Iovance Biotherapeutics on May 9 and set a price target of $18.00. The company's shares closed last Friday at $1.75.
According to TipRanks.com, Zhu has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -5.6% and a 26.4% success rate. Zhu covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Crispr Therapeutics AG, and Taysha Gene Therapies.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Iovance Biotherapeutics with a $13.83 average price target, representing a 612.9% upside. In a report issued on May 8, TD Cowen also maintained a Buy rating on the stock with a $5.00 price target.
Alector (ALEC)
BTIG analyst Thomas Shrader maintained a Buy rating on Alector on May 9 and set a price target of $5.00. The company's shares closed last Friday at $1.17.
According to TipRanks.com, Shrader is a 2-star analyst with an average return of 0.2% and a 33.8% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Coya Therapeutics, Inc., Acumen Pharmaceuticals, and Arcturus Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alector with a $5.50 average price target, which is a 428.8% upside from current levels. In a report issued on May 8, TD Cowen also maintained a Buy rating on the stock.